HKD 16.95 average target for Sinopharm stock from 14 ratings

Published on 10/15/2026 at 18:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue fell 1.13 percent to RMB 282.80 billion in first-half 2026. Sinopharm stock costs EUR 1.80 on October 15, 2026, up 0.32 percent on HKEX.

Average target and next report

Barron's average target was HKD 16.95 from 14 ratings on October 14, 2026.
First-half 2026 revenue fell 1.13 percent to RMB 282.80 billion.
Sinopharm stock costs EUR 1.80 at Lang & Schwarz on October 15, 2026 at 6:32 p.m. CEST, up 0.32 percent on HKEX versus the prior close of October 14, 2026.
Sinopharm is scheduled to report second-quarter 2026 earnings on November 2, 2026.

Sinopharm, CNE100000FN7, Illustration mit AI erstellt.

Barron's reported on October 14, 2026 that the average price target for Sinopharm was HKD 16.95 from 14 ratings. That target stands 8.31 percent above the HKD 15.65 Hong Kong price. Sinopharm stock was trading at EUR 1.80 at Lang & Schwarz on October 15, 2026 at 6:32 p.m. CEST, up 0.32 percent on HKEX versus the prior close of October 14, 2026.

First-half revenue fell 1.13 percent

The latest published operating picture is weaker at the group level. FilingReader reported that operating income for the six months ended June 30, 2026, fell 1.13 percent year over year to RMB 282.80 billion. Net profit declined 2.95 percent to RMB 5.18 billion, while retail pharmacy revenue grew 8.58 percent to RMB 18.64 billion.

The figures point to a split operating profile. Pharmaceutical distribution revenue fell 1.39 percent to RMB 215.50 billion, while medical device distribution revenue declined 0.35 percent to RMB 56.85 billion. Retail pharmacy was the clearest growth contributor in the first half of 2026.

Stock stays near its yearly low

On HKEX, Sinopharm last stood at HKD 15.65 on October 15, 2026 at 4:08 p.m. HKT. The session range was HKD 15.50 to HKD 15.77, while the 52-week range was HKD 14.55 to HKD 22.34. The stock was down 20.06 percent year to date.

The distance to the 52-week low was 7.56 percent, calculated from HKD 15.65 and HKD 14.55. The market is therefore pricing a broad recovery gap to the yearly high, while the latest session remained close to the lower end of the range.

Valuation and the next report

Sinopharm's market capitalization was HKD 48.8 billion, with a trailing P/E ratio of 5.92 and a dividend yield of 5.08 percent. The next scheduled reporting date is November 2, 2026, when the company is expected to publish second-quarter 2026 earnings.

Comparison with peers

Sinopharm (HKEX, HKD): plus 0.32 percent, P/E 5.92, market capitalization HKD 48.8 billion

CSPC Pharmaceutical (HKEX, HKD): plus 0.62 percent, P/E 11.63, market capitalization HKD 101.1 billion

Sino Biopharmaceutical (HKEX, HKD): plus 2.03 percent, P/E 33.99, market capitalization HKD 93.9 billion

Price and investor context

The current picture combines a low valuation multiple with falling first-half group revenue and a retail pharmacy segment that is still expanding. The November 2, 2026 reporting date offers the next concrete test of whether that mix is changing.

Sinopharm stock was trading at EUR 1.80 at Lang & Schwarz on October 15, 2026 at 6:32 p.m. CEST, up 0.32 percent on HKEX versus the prior close of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Sinopharm stock.